Reviewing Nanobiotix (NASDAQ:NBTX) & XBiotech (NASDAQ:XBIT)

XBiotech (NASDAQ:XBIT) and Nanobiotix (NASDAQ:NBTX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Institutional & Insider Ownership

55.7% of XBiotech shares are owned by institutional investors. Comparatively, 38.8% of Nanobiotix shares are owned by institutional investors. 30.8% of XBiotech shares are owned by company insiders. Comparatively, 3.5% of Nanobiotix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

XBiotech has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500.

Profitability

This table compares XBiotech and Nanobiotix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-31.62%	-30.29%
Nanobiotix	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current ratings and price targets for XBiotech and Nanobiotix, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1	0	0	0	1.00
Nanobiotix	1	1	4	0	2.50

Nanobiotix has a consensus price target of $37.33, indicating a potential downside of 11.22%. Given Nanobiotix’s stronger consensus rating and higher possible upside, analysts clearly believe Nanobiotix is more favorable than XBiotech.

Earnings and Valuation

This table compares XBiotech and Nanobiotix”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54 million	($1.48)	-1.56
Nanobiotix	$36.87 million	57.73	-$27.11 million	N/A	N/A

Nanobiotix has higher revenue and earnings than XBiotech.

Summary

Nanobiotix beats XBiotech on 7 of the 10 factors compared between the two stocks.

About XBiotech

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

About Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.